About Viva Biotech
Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage structure-based drug R&D to commercial manufacturing to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, ASMS, SPR, HDX, CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharmaceutical, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

As of December 31, 2023, Viva Biotech has provided drug R&D and production services to 2,278 biotech and pharmaceutical clients around the world. We have invested and incubated 92 biotech start-ups in total. In the future, the Company will continue to strengthen its technical barriers and improve R&D, production levels, and our service capacity to provide high-quality and diversified services for more drug discovery start-ups, as well as medium and large pharmaceutical enterprises around the world.

  • 2,278
    Biotech and pharmaceutical clients worldwide
  • 2,077
    Employees worldwide
  • 67
    Domestic and foreign patents
  • 92
    Invested and incubated companies
Drug R&D Services

With its leading position in Structure-Based Drug Discovery (SBDD), Viva provides state-of-the-art drug research and development services to global biotechnology and pharmaceutical customers for their preclinical, innovative drug discovery programs. We cover the all-around needs of our clients for their early drug research and development, including protein expression, purification and structure determination, hits screening, therapeutic antibody discovery, antibody expression and production, Bioassay, computer-aided drug design, medicinal chemistry and custom synthesis, ADME, and PK studies.

Learn more
R&D and Production Services
As the subsidiary of Viva Biotech holdings, Langhua offers our worldwide partners One-Stop CDMO solution in new drug full life-cycle for small molecule Active Pharmaceutical Ingredients (APIs) and Finished Dosage Form, from pre-clinical to commercial supply.
Learn more
Langhua Pharmaceutical

Langhua Pharmaceutical, a subsidiary of Viva Biotech Holdings, is a comprehensive pharmaceutical company engaged in drug research, development and production. Langhua offers our worldwide partners a One-Stop CDMO solution in new drug full life-cycle for small molecule Active Pharmaceutical Ingredients (APIs) and Finished Dosage Form, from pre-clinical to commercial supply.

SYNthesis med chem

SYNthesis, as a subsidiary of Viva Biotech Holdings, has a highly synergistic new drug development services and project management business that builds on the strengths of Viva's world leading one-stop platform from early-stage SBDD to commercial drug delivery. SYNthesis med chem is a provider of small molecule drug discovery services. Our focus is on the provision of world class medicinal and synthetic chemistry. We fit seamlessly into a client’s company to add capacity and insight to their drug discovery programs. We work with your scientists to accelerate programs from hit-to-lead through to lead optimisation and beyond. With a team of experienced biotech professionals we can contribute to an internal program or independently run a discovery effort. We understand the need for flexibility and cost effectiveness in drug discovery and aim to provide a scalable service to our clients.